[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exicure Inc (XCUR)

Exicure Inc (XCUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,297
  • Shares Outstanding, K 6,374
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,950 K
  • EBIT $ -9 M
  • EBITDA $ -8 M
  • 60-Month Beta 3.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.29

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.71 +28.65%
on 06/16/26
3.45 -36.23%
on 06/02/26
-0.99 (-31.03%)
since 05/29/26
3-Month
1.71 +28.65%
on 06/16/26
4.51 -51.23%
on 03/30/26
-2.21 (-50.17%)
since 03/27/26
52-Week
1.71 +28.65%
on 06/16/26
9.50 -76.84%
on 07/21/25
-3.69 (-62.65%)
since 06/27/25

Most Recent Stories

More News
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department...

XCUR : 2.20 (-8.33%)
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) --  Exicure, Inc. (Nasdaq: XCUR, the “Company”)  announced today that it received a notification letter from the Listing Qualifications Department...

XCUR : 2.20 (-8.33%)
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology...

XCUR : 2.20 (-8.33%)
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following...

XCUR : 2.20 (-8.33%)
Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial...

XCUR : 2.20 (-8.33%)
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication...

XCUR : 2.20 (-8.33%)
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it...

XCUR : 2.20 (-8.33%)
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive...

XCUR : 2.20 (-8.33%)
Exicure, Inc. Reports Third Quarter 2025 Financial Results

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025. ...

XCUR : 2.20 (-8.33%)
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results...

XCUR : 2.20 (-8.33%)

Business Summary

Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States.

See More

Key Turning Points

3rd Resistance Point 2.65
2nd Resistance Point 2.56
1st Resistance Point 2.38
Last Price 2.20
1st Support Level 2.11
2nd Support Level 2.02
3rd Support Level 1.84

See More

52-Week High 9.50
Fibonacci 61.8% 6.52
Fibonacci 50% 5.61
Fibonacci 38.2% 4.69
Last Price 2.20
52-Week Low 1.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.